What is/are Captopril/Hctz?
Captopril (rINN) /ˈkæptəprɪl/ is an angiotensin-converting enzyme (ACE) inhibitor used for the treatment of hypertension and some types of congestive heart failure. Captopril was the first ACE inhibitor developed and was considered a breakthrough both because of its novel mechanism of action and also because of the revolutionary development process. Captopril is commonly marketed by Bristol-Myers Squibb under the trade name Capoten.
Captopril's main uses are based on its vasodilation and inhibition of some renal function activities. These benefits are most clearly seen in the following conditions:
2) Cardiac conditions such as congestive heart failure and after myocardial infarction
3) Preservation of kidney function in diabetic nephropathy
Additionally, it has shown mood-elevating properties in some patients. This is consistent with the observation that animal screening models indicate putative antidepressant activity for this compound, although there has been one negative study. Formal clinical trials in depressed patients have not been reported. It has also been investigated for use in the treatment of cancer.
Adverse effects of captopril include cough due to increase in the plasma levels of bradykinin, angioedema, agranulocytosis, proteinuria, hyperkalemia, taste alteration, teratogenicity, postural hypotension, acute renal failure and leukopenia. Except for postural hypotension, which occurs due to short and fast mode of action of captopril, most of the side effects mentioned are common for all ACE inhibitors. Among these, cough is the most common adverse effect. Hyperkalemia can occur, especially if used with other drugs which elevate potassium level in blood, such as potassium-sparing diuretics. Other side effects are:
- Chest pain
Mnemonic for CAPTOPRIL side effects: Cough, Angioedema, Proteinuria, Taste change, hypOtension, Pregnancy problems, Rash, Increased renin, Lower pressure (lack of vasoconstriction)
This article uses material from the Wikipedia article Captopril/Hctz, which is released under the Creative Commons Attribution-Share-Alike License 3.0.